Novel approaches in the therapy of metastatic renal cell carcinoma

World Journal of Urology

Volumn 23, Issue 3, 2005, Pages 202-212

  Lam, John S ^a   Leppert, John T ^a   Belldegrun, Arie S ^a   Figlin, Robert A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti angiogenesis; Cancer; Carbonic anhydrase IX; Kidney; Metastases; Small molecule inhibitors; Therapy

Indexed keywords

HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY TUMOR; METASTASIS; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; REVIEW;

CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 23744445106     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00345-004-0466-0     Document Type: Review

References (98)

1. Antonia SJ, Seigne J, Diaz J, Muro-Cacho C, Extermann M, Farmelo MJ, Friberg M, Alsarraj M, Mahany JJ, Pow-Sang J, Cantor A, Janssen W (2002) Phase I trial of a B7 - 1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol 167:1995-2000 10.1097/00005392-200205000-00014
2. Assikis VJ, Daliani L, Pagliaro L, Wood C, Perez C, Logothetis C, Papandreou C, Hawkins ES, Srivastava PK (2003) Phase II study of an autologous tumor derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol 22:386
3. Atkins M, McDermott D, Mier J, Stanbridge E, Youmans A, Polivy A, Regran M, Connolly C, Febbo P, Upton M, Lechpammer M, Signoretti S (2004) Carbonic anhydrase IX (CAIX) expression predicts for renal cell cancer (RCC) patient response and survival to IL-2 therapy. Proc Am Soc Clin Oncol 23:383
4. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909-918
5. Avigan DE, George DJ, Kantoff PW, Figlin RA, Kufe DW, Olencki TE, Vasconcelles MJ, Vasir BS, Xu Y, Bukowski RM (2004) Interim safety and efficacy results from a phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. Proc Am Soc Clin Oncol 23:169
6. Baba M, Hirai S, Yamada-Okabe H, Hamada K, Tabuchi H, Kobayashi K, Kondo K, Yoshida M, Yamashita A, Kishida T, Nakaigawa N, Nagashima Y, Kubota Y, Yao M, Ohno S (2003) Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Oncogene 22:2728-2738 10.1038/sj.onc.1206373
7. Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, Polychronis A, Pandha H, Muller GW, Stirling DI, Zeldis J, Dalgleish AG (2004) Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 90:955-961 10.1038/sj.bjc.6601579
8. Batist G, Patenaude F, Champagne P, Croteau D, Levinton C, Hariton C, Escudier B, Dupont E (2002) Neovastat (AE-941) in refractory renal cell carcinoma patients: Report of a phase II trial with two dose levels. Ann Oncol 13:1259-1263 10.1093/annonc/mdf195
9. Bevan P, Mala C, Kindler M, Siebels M, Oberneder R, Beck HJ (2004) Results of a phase I/II study with monoclonal antibody CG250 in combination with IFNα-2A in metastatic renal cell carcinoma patients. Proc Am Soc Clin Oncol 23:407
10. Bindra RS, Vasselli JR, Stearman R, Linehan WM, Klausner RD (2002) VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 62:3014-3019 12036906
11. Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C, Kruit W, Melchior S, Mala C, Ullrich S, Mulder PD, Mulders PF, Beck J (2004) A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 90:985-990 10.1038/sj.bjc.6601617
12. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, Belldegrun AS (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9:802-811
13. Bukowski RM (1997) Natural history and therapy of metastatic renal cell carcinoma: The role of interleukin-2. Cancer 80:1198-1220 10.1002/ (SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H
14. Castillo M, Petit A, Mellado B, Palacin A, Alcover JB, Mallofre C (2004) C-kit expression in sarcomatoid renal cell carcinoma: Potential therapy with imatinib. J Urol 171:2176-2180 10.1097/01.ju.0000127727.33232.cf
15. Chang DZ, Olencki T, Budd GT, Peereboom D, Ganapathi R, Osterwalder B, Bukowski R (2001) Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: Toxicity and pharmacokinetics. Cancer Chemother Pharmacol 48:493-498
16. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P, Harris AL (2001) Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 19:3660-3668
17. Chow WH, Devesa SS, Warren JL, Fraumeni JFJr (1999) Rising incidence of renal cell cancer in the United States. JAMA 281:1628-1631 10.1001/jama.281.17.1628
18. Daliani DD, Papandreou CN, Thall PF, Wang X, Perez C, Oliva R, Pagliaro L, Amato R (2002) A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 95:758-765 10.1002/cncr.10740
19. Davidowitz EJ, Schoenfeld AR, Burk RD (2001) VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol Cell Biol 21:865-874 10.1128/MCB.21.3.865-874.2001
20. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM (2004) Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago phase II consortium study. J Clin Oncol 22:115-119
21. De Paulsen N, Brychzy A, Fournier MC, Klausner RD, Gnarra JR, Pause A, Lee S (2001) Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci U S A 98:1387-1392 10.1073/pnas.031587498
22. Divgi CR, Bander NH, Scott AM, O'Donoghue JA, Sgouros G, Welt S, Finn RD, Morrissey F, Capitelli P, Williams JM, Deland D, Nakhre A, Oosterwijk E, Gulec S, Graham MC, Larson SM, Old LJ (1998) Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 4:2729-2739
23. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037 10.1056/NEJM200104053441401
24. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE, Gore ME (2000) Continuous low dose Thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82:812-817
25. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL (1999) Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 59:3915-3918
26. Figlin RA (1999) Renal cell carcinoma: Management of advanced disease. J Urol 161:381-387 10.1097/00005392-199902000-00002
27. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JRJr, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655-1659 10.1056/NEJMoa003013
28. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL (2002) Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277:38205-38211 10.1074/jbc.M203781200
29. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688-696
30. Gitlitz BJ, Belldegrun AS, Zisman A, Chao DH, Pantuck AJ, Hinkel A, Mulders P, Moldawer N, Tso CL, Figlin RA (2003) A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother 26:412-419 10.1097/00002371-200309000-00004
31. Gitlitz BJ, Figlin RA (2003) Cytokine-based therapy for metastatic renal cell cancer. Urol Clin North Am 30:589-600
32. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM et al. (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85-90
33. Grabmaier K, Vissers JL, De Weijert MC, Oosterwijk-Wakka JC, Van Bokhoven A, Brakenhoff RH, Noessner E, Mulders PA, Merkx G, Figdor CG, Adema GJ, Oosterwijk E (2000) Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 85:865-870 10.1002/(SICI)1097-0215(20000315)85:6<865::AID-IJC21>3.0.CO;2-Q
34. Harris AL (2002) Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2:3-47.
35. Hernandez JM, Bui MH, Han KR, Mukouyama H, Freitas DG, Nguyen D, Caliliw R, Shintaku PI, Paik SH, Tso CL, Figlin RA, Belldegrun AS (2003) Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. Clin Cancer Res 9:1906-1916
36. Hernberg M, Virkkunen P, Bono P, Ahtinen H, Maenpaa H, joensuu H (2003) Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol 21:3770-3776
37. Holtl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, Radmayr C, Stenzl A, Bartsch G, Thurnher M (1999) Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 161:777-782 10.1097/00005392-199903000-00009
38. Medical Research Council Renal Cancer Collaborators (1999) Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Lancet 353:14-17 10.1016/ S0140-6736(98)03544-2
39. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM (2002) Hsp90 regulates a von Hippel-Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277:29936-29944 10.1074/ jbc.M204733200
40. Janzen NK, Kim HL, Figlin RA, Belldegrun AS (2003) Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30:843-852
41. Jemal A, Murray T, Ward E, Samuels A,Tiwari RC, Ghafoor A, Feur EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10-30
42. Jiang BH, Agani F, Passaniti A, Semenza GL (1997) V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 57:5328-5335
43. Kaufman B, Scharf O, Arbeit J, Ashcroft M, Brown JM, Bruick RK, Chapman JD, Evans SM, Giaccia AJ, Harris AL, Huang E, Johnson R, Kaelin WJr, Koch CJ, Maxwell P, Mitchell J, Neckers L, Powis G, Rajendran J, Semenza GL, Simons J, Storkebaum E, Welch MJ, Whitelaw M, Melillo G, Ivy SP (2004) Proceedings of the Oxygen Homeostasis/Hypoxia Meeting. Cancer Res 64:3350-3356
44. Knebelmann B, Ananth S, Cohen HT, Sukhatme VP (1998) Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 58:226-231
45. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS (2005) Renal cell carcinoma 2005: New frontiers in staging, prognostication, and targeted molecular therapy. J Urol (in press)
46. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML (2002) Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295:858-861 10.1126/science.1068592
47. Lebret T, Watson RW, Fitzpatrick JM (2003) Heat shock proteins: Their role in urological tumors. J Urol 169:338-346 10.1097/ 00005392-200301000-00103
48. Lee Y, Vassilakos A, Feng N, Lam V, Xie H, Wang M, Jin H, Xiong K, Liu C, Wright J, Young A (2003) GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Res 63:2802-2811 1:CAS:528:DC%2BD3sXkt1ais78%3D
49. Linehan WM, Vasselli J, Srinivasan R, Walther MM, Merino M, Choyke P, Vocke C, Schmidt L, Isaacs JS, Glenn G, Toro J, Zbar B, Bottaro D, Neckers L (2004) Genetic basis of cancer of the kidney: Disease-specific approaches to therapy. Clin Cancer Res 10:6282S-6289S
50. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ, West CM (2001) Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: Correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61:6394-6399 1:CAS:528:DC%2BD3MXmsF2jsLo%3D
51. Mahon PC, Hirota K, Semenza GL (2001) FIH-1: A novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15:2675-2686 10.1101/gad.924501
52. Makino Y, Kanopka A, Wilson WJ, Tanaka H, Poellinger L (2002) Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J Biol Chem 277:32405-32408 10.1074/jbc.C200328200
53. Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH, Figg WD, Wainer I, Chaissang C, Li MZ, Hawkins MJ (2002) A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2:325-332 10.1046/j.1359-4117.2002.01039.x
54. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275 10.1038/20459
55. Mickisch GH, Garin A, Van Poppel H, De Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial. Lancet 358:966-970 10.1016/S0140-6736(01)06103-7
56. Motzer RJ, Amato R, Todd M, Hwu WJ, Cohen R, Baselga J, Muss H, Cooper M, Yu R, Ginsberg MS, Needle M (2003) Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21:99-101 10.1023/A:1022928612511
57. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V (2002) Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20:2376-2381
58. Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, Bacik J, Mazumdar M (2002) Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 20:302-306
59. Motzer RJ, Rini BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Zhu J, Kim ST, Baum C (2004) SUO11248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial. Proc Am Soc Clin Oncol 23:381
60. Motzer RJ, Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163:408-417 1:STN:280:DC%2BD3c7ht1Wluw%3D%3D
61. Mukouyama H, Janzen NK, Hernandez JM, Lam JS, Caliliw R, Wang AY, Figlin RA, Belldegrun AS, Zeng G (2004) Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9. Clin Cancer Res 10:1421-1429
62. Na X, Wu G, Ryan CK, Schoen SR, Di'Santagnese PA, Messing EM (2003) Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol 170:588-592 10.1097/01.ju.0000074870.54671.98
63. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 98:10314-10319 10.1073/pnas.171076798
64. Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, Turner ML, Duray P, Merino M, Choyke P, Pavlovich CP, Sharma N, Walther M, Munroe D, Hill R, Maher E, Greenberg C, Lerman MI, Linehan WM, Zbar B, Schmidt LS (2002) Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2:157-164 10.1016/ S1535-6108(02)00104-6
65. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG (2000) Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2:423-427 10.1038/35017054
66. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WGJr, Iliopoulos O (1998) The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1:959-968 10.1016/ S1097-2765(00)80096-9
67. Olive PL, Aquino-Parsons C, MacPhail SH, Liao SY, Raleigh JA, Lerman MI, Stanbridge EJ (2001) Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 61:8924-8929
68. Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson SM, Warnaar SO, Fleuren GJ et al. (1993) Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. J Clin Oncol 11:738-750
69. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, Pauwels EK, Jonas U, Zwartendijk J, Warnaar SO (1986) Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 38:489-494
70. Opavsky R, Pastorekova S, Zelnik V, Gibadulinova A, Stanbridge EJ, Zavada J, Kettmann R, Pastorek J (1996) Human MN/CA9 gene, a novel member of the carbonic anhydrase family: Structure and exon to protein domain relationships. Genomics 33:480-487 10.1006/geno.1996.0223
71. Pantuck AJ, Belldegrun AS, Figlin RA (2001) Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med 345:1711-1712 10.1056/NEJM200112063452317
72. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA (2003) Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: Exploiting the hypoxia-induced pathway. Clin Cancer Res 9:4641-4652
73. Pavlovich CP, Schmidt LS (2004) Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer 4:381-393 10.1038/nrc1364
74. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100:8372-8377
75. Pisani P, Parkin DM, Bray F, Ferlay J (1999) Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83:18-29 10.1002/ (SICI)1097-0215(19990924)83:1<18::AID-IJC5>3.3.CO;2-D
76. Ratain MJ, Flaherty KT, Stadler WM, O'Dwyer P, Kaye S, Xiong H, Patnaik A, Gore M, Lee RJ, Eisen T (2004) Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trail (RDT). Proc Am Soc Clin Oncol 23:381
77. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, Bedi A (2000) Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14:34-44
78. Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R, Haas N, Lockbaum P, Li YP, Arends R, Foon KA, Schwab G, Dutcher J (2004) Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22:3003-3015
79. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Zbar B et al. (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68-73 10.1038/ng0597-68
80. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, Lubensky I, Neumann HP, Brauch H, Decker J, Vocke C, Brown JA, Jenkins R, Richard S, Bergerheim U, Gerrard B, Dean M, Linehan WM, Zbar B (1999) Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18:2343-2350 10.1038/sj.onc.1202547
81. Schmidt L, Junker K, Weirich G, Glenn G, Choyke P, Lubensky I, Zhuang Z, Jeffers M, Vande Woude G, Neumann H, Walther M, Linehan WM, Zbar B (1998) Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 58:1719-1722
82. Semenza GL (2002) HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol Med 8:S62-67 10.1016/S1471-4914(02)02317-1
83. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W (2003) Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425:307-311 1:CAS:528:DC%2BD3sXntlWnsrk%3D
84. Stebbing J, Benson C, Eisen T, Pyle L, Smalley K, Bridle H, Mak I, Sapunar F, Ahern R, Gore ME (2001) The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 85:953-958 10.1038/ sj.bjc.6692025
85. Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J (2003) Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 63:2127-2133 1:CAS:528:DC%2BD3sXjtlGmtr4%3D
86. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, Roylance RR, Olpin S, Bevan S, Barker K, Hearle N, Houlston RS, Kiuru M, Lehtonen R, Karhu A, Vilkki S, Laiho P, Eklund C, Vierimaa O, Aittomaki K, Hietala M, Sistonen P, Paetau A, Salovaara R, Herva R, Launonen V, Aaltonen LA (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30:406-410 10.1038/ng849
87. Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, De Kernion J, Figlin R, Belldegrun A (2001) Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res 61:7925-7933
88. Turner KJ, Crew JP, Wykoff CC, Watson PH, Poulsom R, Pastorek J, Ratcliffe PJ, Cranston D, Harris AL (2002) The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br J Cancer 86:1276-1282 10.1038/sj.bjc.6600215
89. Tyers M, Rottapel R (1999) VHL: A very hip ligase. Proc Natl Acad Sci U S A 96:12230-12232 10.1073/pnas.96.22.12230
90. Uemura H, Nakagawa Y, Yoshida K, Saga S, Yoshikawa K, Hirao Y, Oosterwijk E (1999) MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 81:741-746 10.1038/ sj.bjc.6690757
91. Vissers JL, De Vries IJ, Engelen LP, Scharenborg NM, Molkenboer J, Figdor CG, Oosterwijk E, Adema GJ (2002) Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-DR molecules to CD4(+) T lymphocytes. Int J Cancer 100:441-444 10.1002/ijc.10518
92. Vissers JL, De Vries IJ, Schreurs MW, Engelen LP, Oosterwijk E, Figdor CG, Adema GJ (1999) The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 59:5554-5559 1:CAS:528:DyaK1MXnt1Gisro%3D
93. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434 10.1056/NEJMoa021491
94. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21:3127-3132 10.1200/JCO.2003.02.122
95. Yao M, Yoshida M, Kishida T, Nakaigawa N, Baba M, Kobayashi K, Miura T, Moriyama M, Nagashima Y, Nakatani Y, Kubota Y, Kondo K (2002) VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 94:1569-1575
96. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW (2003) YC-1: A potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95:516-525
97. Zavada J, Zavadova Z, Pastorek J, Biesova Z, Jezek J, Velek J (2000) Human tumour-associated cell adhesion protein MN/CA IX: Identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer 82:1808-1813
98. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541-1545 1:CAS:528:DC%2BD3cXit1aqt74%3D